

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating anxiety comprising ~~the step of~~ introducing into the central nervous system of a subject in need thereof a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV (DP IV) enzyme whereby enzymatic activity of said enzyme is reduced.
2. (Currently Amended) A method for reducing degradation of the endogenous CNS-localized neuropeptide Y (NPY) for the treatment of anxiety, the method comprising ~~the step of~~ introducing into the central nervous system of a subject in need thereof a therapeutically effective amount of a competitive inhibitor of dipeptidyl peptidase (DP IV).
3. (Previously Presented) The method of claim 1 wherein said inhibitor is selected from the group consisting of N-(N'-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.
4. (Previously Presented) The method of claim 1 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.
5. (Currently Amended) ~~A~~ The method of claim 1 wherein said inhibitor is of treating anxiety comprising introducing into the central nervous system a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV enzyme formulated in combination with NPY.
6. (Previously Presented) The method of claim 1 wherein introducing of said inhibitor of dipeptidyl peptidase IV is parenteral.
7. (Previously Presented) The method of claim 2 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.
8. (Cancelled)
9. (Previously Presented) The method of claim 3 wherein said inhibitor is formulated as prodrug of the free inhibitors.

10. (Previously Presented) The method of claim 2 wherein said introducing of said DP IV-inhibitor is parenteral.

11. (Previously Presented) The method of claim 3 wherein said introducing of said DP IV-inhibitor is parenteral.

12. (Previously Presented) The method of claim 4 wherein said introducing of said DP IV-inhibitor is parenteral.

13. (Currently Amended) The method of claim 5 wherein said introducing of said DP IV-inhibitor in combination with NPY is applied parenteral.

14. (Previously Presented) The method of claim 2, wherein said DP IV-inhibitor is selected from the group consisting of N-(N'-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.

15. (Previously Presented) The method of claim 5, wherein said DP IV-inhibitor is selected from the group consisting of N-(N'-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine